Challenges Encountered in the Implementation of Bio-Fluorescent Particle Counting Systems as a Routine Microbial Monitoring Tool

References

1. 1.↵
   1. Ammor M. S.

   Recent Advances in the Use of Intrinsic Fluorescence for Bacterial Identification and Characterization. J. Fluoresc. 2007, 17 (5), 455–459.

   OpenUrlPubMedGoogle Scholar
2. 2.↵
   1. Irie K.,
   2. Scott A.,
   3. Hasegawa N.

   Investigation of the Detection Ability of an Intrinsic Fluorescence-Based Bioaerosol Detection System for Heat-Stressed Bacteria. PDA J. Pharm. Sci. Technol. 2014, 68 (5), 478–493.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
3. 3.↵
   1. Miller M. J.,
   2. Lindsay H.,
   3. Valverde-Ventura R.,
   4. O'Conner M. J.

   Evaluation of the BioVigilant IMD-A, a Novel Optical Spectroscopy Technology for the Continuous and Real-Time Environmental Monitoring of Viable and Nonviable Particles. Part I: Review of the Technology and Comparative Studies with Conventional Methods. PDA J. Pharm. Sci. Technol. 2009, 63 (3), 245–258.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
4. 4.↵
   1. Cundell A.,
   2. Gordon O.,
   3. Haycocks N.,
   4. Johnston J.,
   5. Luebke M.,
   6. Lewis N.,
   7. Mateffy J.,
   8. Weber J.-W.

   Novel Concept for Online Water Bioburden Analysis: Key Considerations, Applications, and Business Benefits for Microbiological Risk Reduction. Amer. Pharm. Rev. [Online] 2013, 16 (3), 26–31. https://www.americanpharmaceuticalreview.com/Featured-Articles/140513-Novel-Concept-for-Online-Water-Bioburden-Analysis-Key-Considerations-Applications-and-Business-Benefits-for-Microbiological-Risk-Reduction/ (accessed June 27, 2021).

   OpenUrlGoogle Scholar
5. 5.↵
   1. Moldenhauer J.

   Environmental Monitoring: A Comprehensive Handbook, Volume 2; Moldenhauer J., Ed.; DHI Publishing LLC: River Grove, IL, 2005; p 459.

   Google Scholar
6. 6.↵
   1. Agranovski V.,
   2. Ristovski Z.,
   3. Hargreaves M.,
   4. Blackall P. J.,
   5. Morawska L.

   Performance Evaluation of the UVAPS: Influence of Physiological Age of Airborne Bacteria and Bacterial Stress. J. Aerosol Sci. 2003, 34 (12), 1711–1727.

   OpenUrlCrossRefGoogle Scholar
7. 7.↵
   U.S. Food and Drug Administration. Guidance for Industry PAT –A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance. Center for Drug Evaluation and Research, U.S. Department of Health and Human Services: Rockville, MD, 2004.

   Google Scholar
8. 8.↵
   1. Scott A.,
   2. Forng R.-Y.,
   3. Russ M.,
   4. Dalmaso G.,
   5. Hooper S.,
   6. Villari P.,
   7. Cannon J.,
   8. Francis J.,
   9. Dingle M.

   A Discussion on Bio-Fluorescent Particle Counters: Summary of the Process and Environmental Monitoring Methods Working Group Meeting with the FDA Emerging Technology Team. PDA J. Pharm. Sci. Technol. 2021, 75 (2), 207–212.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
9. 9.↵
   1. Weber J.,
   2. Hauschild J.,
   3. IJzerman-Boon P.,
   4. Forng R.-Y.,
   5. Horsch J.,
   6. Yan L.,
   7. Prasad A.,
   8. Henry R.,
   9. Claassen M.,
   10. Villari P.,
   11. Shereefa S.,
   12. Wyatt J.,
   13. Bolden J. S.,
   14. Pycke J.-T.,
   15. Dassu D.

   Continuous Microbiological Environmental Monitoring for Process Understanding and Reduced Interventions in Aseptic Manufacturing. PDA J. Pharm. Sci. Technol. 2019, 73 (2), 121–134.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
10. 10.↵
    1. Prasad A.,
    2. Scott A.,
    3. Manzer D.,
    4. Weber J.,
    5. Chen J.-P.,
    6. Lawson L.,
    7. Dingle M.,
    8. Noverini P.,
    9. Villari P.,
    10. Hooper S.

    Bio-Fluorescent Particle Counter-Based Real-Time Feedback and Control of Processing Conditions. Eur. Pharm. Rev. [Online] 2019, (5). https://www.europeanpharmaceuticalreview.com/article/98107/biofluorescent-particle-counter-based-real-time-feedback-and-control-of-processing-conditions/ (accessed June 27, 2021).

    Google Scholar
11. 11.↵
    1. Anders H.-J.,
    2. Ayers F.,
    3. Fitch B.,
    4. Forng R.-Y.,
    5. Hooper S.,
    6. Luebke M.,
    7. Mateffy J.,
    8. Noverini P.,
    9. Termine B.,
    10. Yan L.,
    11. Weber J.

    Practical Application of Online Water Bioburden Analyzers in Pharmaceutical Manufacturing. Pharm. Online [Online] 2017. https://www.pharmaceuticalonline.com/doc/practical-application-of-online-water-bioburden-analyzers-in-pharmaceutical-manufacturing-0001 (accessed June 27, 2021).

    Google Scholar
12. 12.↵
    Online Water Bioburden Analyzer Workgroup. A Better Approach to Pharmaceutical Water Testing – User Requirements for an Online Water Bioburden Analyzer. Pharm. Online [Online] 2018. https://www.pharmaceuticalonline.com/doc/a-better-approach-to-pharmaceutical-water-testing-user-requirements-for-an-online-water-bioburden-analyzer-0001 (accessed June 27, 2021).

    Google Scholar
13. 13.↵
    1. Prasad A.,
    2. Villari P.,
    3. Henry R.,
    4. Weber J.,
    5. Hauschild J.,
    6. Yan L.,
    7. Horsch J.,
    8. Shereefa S.,
    9. Rau J. E.,
    10. Milling A.,
    11. Bolden J. S.,
    12. Plourde L.,
    13. Claassen M.,
    14. IJzerman-Boon P.,
    15. Forng R.-Y.,
    16. Portmann R.,
    17. Urwyler S.,
    18. Dassu D.

    Practical Applications of Bio-Fluorescent Particle Counting in Environmental Monitoring Investigations. PDA J. Pharm. Sci. Technol. 2020, 74 (3), 318–323.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
14. 14.↵
    1. Epstein S. S.

    Uncultivated Microorganisms; Epstein S. S., Ed.; Springer: New York, 2009.

    Google Scholar
15. 15.↵
    U.S. Pharmacopeial Convention. General Chapter <1223> Validation of Alternative Microbiological Methods. In USP 38–NF 33, USP: Rockville, MD, 2015.

    Google Scholar
16. 16.↵
    European Commission, EudraLex—The Rules Governing Medicinal Product in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products. European Commission: Brussels, 2010.

    Google Scholar
17. 17.↵
    European Commission. Second Targeted Stakeholders' Consultation on the Draft Revision 12 of Annex 1, on Manufacturing of Sterile Medicinal Products, of Eudralex Volume 4. https://ec.europa.eu/health/medicinal_products/consultations/2020_sterile_medicinal_products_en (accessed August 15, 2021)

    Google Scholar
18. 18.↵
    1. Hussong D.,
    2. Mello R.

    Alternative Microbiology Methods and Pharmaceutical Quality Control. Am. Pharm. Rev. [Online] 2006. https://www.americanpharmaceuticalreview.com/Featured-Articles/113093-Alternative-Microbiology-Methods-and-Pharmaceutical-Quality-Control/ (accessed June 27, 2021).

    Google Scholar
19. 19.↵
    1. Cundell T.

    The Limitations of the Colony Forming Unit in Microbiology. Eur. Pharm. Rev. [Online] 2015, 20 (6), 11–13. https://www.europeanpharmaceuticalreview.com/article/37416/the-limitations-of-the-colony-forming-unit-in-microbiology/ (accessed June 27, 2021).

    OpenUrlGoogle Scholar
20. 20.↵
    Parenteral Drug Association Inc. Technical Report No. 33: Evaluation, Validation and Implementation of Alternative and Rapid Microbiological Methods; Bethesda, MD, 2013.

    Google Scholar
21. 21.↵
    Council of Europe, Alternative Methods for Control of Microbiological Quality, Chapter 5.1.6. In European Pharmacopoeia (Phar. Eur.), Council of Europe: Strasbourg, France, 2015.

    Google Scholar
22. 22.↵
    1. Miller M. J.

    A Fresh Look at USP <1223> Validation of Alternative Microbiological Methods and How the Revised Chapter Compares with PDA TR33 and the Proposed Revision to Ph. Eur. 5.1.6. Am. Pharm. Rev. [Online] 2015, https://www.americanpharmaceuticalreview.com/Featured-Articles/177873-A-Fresh-Look-at-USP-1223-Validation-of-Alternative-Microbiological-Methods-and-How-the-Revised-Chapter-Compares-with-PDA-TR33-and-the-Proposed-Revision-to-Ph-Eur-5-1-6/ (accessed June 27, 2021).

    Google Scholar
23. 23.↵
    U.S. Pharmacopeial Convention. General Chapter <1223> Validation of Alternative Microbiological Methods. In USP 29–NF 24, Suppl. 2, USP: Rockville, MD, 2006; p 3807.

    Google Scholar
24. 24.↵
    U.S. Pharmacopeial Convention. General Chapter <1223> Validation of Alternative Microbiological Methods. In USP 37–NF 32, USP: Rockville, MD, 2014; p 1152.

    Google Scholar
25. 25.↵
    Parenteral Drug Association. Technical Report 33 Evaluation, Validation and Implementation of New Microbiological Testing Methods. PDA J. Pharm. Sci. Technol. 2000, 54 (3, Suppl).

    Google Scholar
26. 26.↵
    Council of Europe. Alternative Methods for Control of Microbiological Quality, Chapter 5.1.6, In European Pharmacopoeia (Ph. Eur.), Council of Europe: Strasbourg, France, 2006.

    Google Scholar
27. 27.↵
    1. Montenegro-Alvarado J.-M.

    Leveraging Rapid Microbiological Methodology in Forensic Evaluation to Identify Elusive Root Cause. Am. Pharm. Rev. [Online] 2018, https://www.americanpharmaceuticalreview.com/Featured-Articles/353500-Leveraging-Rapid-Microbiological-Methodology-in-Forensic-Evaluation-to-Identify-Elusive-Root-Cause/ (accessed June 27, 2021).

    Google Scholar
28. 28.↵
    1. Montenegro-Alvarado J.-M.,
    2. Salvas J.,
    3. Weber J.,
    4. Mejias S.,
    5. Arroyo R.

    Pfizer Case Study: Rapid Microbial Methods for Manufacturing Recovery after Hurricane Maria. Pharm. Online [Online] 2018. Online https://www.pharmaceuticalonline.com/doc/pfizer-case-study-rapid-microbial-methods-for-manufacturing-recovery-after-hurricane-mar-a-0001 (accessed June 27, 2021)

    Google Scholar